Article 83 of the EU MDR, all medical device manufacturers are mandated to prepare and submit a PSUR. This document is essential for devices classified as class IIa, IIb, III, and for all stand-alone software intended for medical purposes. The PSUR provides a systematic review of the benefit-risk balance of the device and offers insights into the safety and efficacy of a product. Specifically, it should include the following key elements:

• Identification of the Device: A detailed description of the device, including its intended purpose, classification, and regulatory status.
• Summary of the Safety Information: A comprehensive summary of data from post-market surveillance (PMS), clinical literature, and real-world evidence regarding the device’s safety profile.
• Analysis of Benefit-Risk Ratio: An assessment of the device’s safety and performance in light of the collected data and evidence.
• Proposed Actions: Recommendations for further action, which may include changes to labeling, additional studies, or safety communications.

The PSUR is generally prepared annually or biennially, depending on the classification risk of the device, unless otherwise required by the competent authorities or notified bodies involved.

Key Components of a PSUR

When composing a PSUR, it is critical to include specific components that fulfill the regulatory requirements and ensure clarity. Below is an outline highlighting the primary components of a PSUR:

• Title Page: Include the document title, device name, manufacturer name, and date.
• Table of Contents: List the sections of the report for easy navigation.
• Executive Summary: Provide a brief overview of the device, safety summaries, and historical context of safety data.
• Device Description: Outline the device’s intended purpose, design, manufacturing process, and any variations in its evolution.
• Data Sources: Detail the sources of safety data, including PMS reports, expected adverse events, and post-market clinical follow-up data.
• Safety Data Analysis: Present findings from adverse event reporting and literature reviews, highlighting any emerging trends.
• Risk Management: Summarize the risk evaluation processes and mitigation strategies employed throughout the device lifecycle.
• Conclusion and Recommendations: End with a succinct conclusion that outlines the overall safety and performance profile, along with recommendations for regulatory actions or continued monitoring.

PSUR Preparation Process: A Step-by-Step Guide

The preparation of a PSUR can be streamlined by following a structured process. Below is a step-by-step approach to assist pharmaceutical regulatory consulting professionals in drafting effective PSURs:

Step 1: Compile Necessary Data

Gather all the relevant safety and performance data from various sources. This may include:

• Post-market surveillance data
• Adverse event reports
• Clinical trial results
• Scientific literature and case reports

Ensure that the data is accurately validated to maintain reliability and integrity.

Step 2: Analyze Safety and Efficacy

Conduct a thorough analysis of the data collected. Ensure you evaluate:

• The frequency and types of reported adverse events
• Possible root causes of adverse events
• The overall benefit-risk profile of the device

It’s essential to engage with key stakeholders during analysis to incorporate various perspectives and insights.

Step 3: Draft the PSUR

Using the key components outlined earlier, start drafting the PSUR. It is important to maintain a clear and concise language throughout. Pay particular attention to the executive summary and ensure that it accurately reflects the findings presented in the detailed sections.

Step 4: Review and Quality Assurance

Once the PSUR draft is prepared, it should undergo thorough reviews to ensure compliance with applicable regulations and internal quality standards. This review should include:

• Regulatory compliance check
• Verification of data accuracy
• Alignment with previous PSUR submissions

Step 5: Submission to Regulatory Authorities

After finalizing the PSUR, the next step is submission to the designated regulatory bodies. This includes:

• The relevant Competent Authority in the EU
• Your notified body
• Any other required stakeholders

Ensure that all submissions align with regional requirements (Regulations 2017/745 for medical devices and 2017/746 for in vitro diagnostic devices) to foster compliance and successful acceptance.

Challenges in Preparing a PSUR

Pharmaceutical regulatory consultants often encounter challenges while preparing PSURs. Understanding these challenges can help organizations proactively mitigate risks. Common issues include:

• Inconsistent Data Collection: Variations in data source quality can lead to incomplete or misleading conclusions.
• Time Constraints: Ensuring timely PSUR submissions while addressing quality concerns can strain resources.
• Regulatory Changes: Staying current with evolving regulations while preparing PSURs can be complex.
• Multifunctional Team Collaboration: Collaborating efficiently with cross-functional teams can be a challenge during the PSUR preparation process.

Utilizing Technology for PSUR Management

Incorporating technology into the PSUR management process can significantly streamline preparation and compliance efforts. Solutions such as Veeva pharmacovigilance systems can support the data collection and analysis components, while also facilitating consistent documentation practices. Below are ways to leverage technology effectively:

• Data Management Systems: Using centralized databases to gather and assess safety data ensures streamlined access and retrieval.
• Automated Reporting Tools: Utilizing software that automates report generation can reduce human error and save time.
• Collaboration Platforms: Implementing collaboration tools facilitates communication and document sharing among team members across different departments.

Conclusion: Ensuring Compliance and Enhancing Safety through Effective PSURs

The preparation of a PSUR in line with the EU MDR requirements is essential for maintaining compliance and ensuring the ongoing safety of medical devices and combination products. Following a structured approach, supported by robust technology solutions and cross-functional collaboration, is paramount for regulatory consultants navigating this complex landscape. By understanding PSUR intricacies, pharmaceutical regulatory consulting professionals can significantly enhance product safety, align with regulatory expectations, and contribute to the wider goal of public health protection.

We encourage all organizations involved in device development and lifecycle management to treat PSURs as a vital component of their overall regulatory strategy. Continual learning, adaptation, and improvement are essential as regulatory frameworks evolve in response to emerging safety challenges.